ATE336587T1 - Adenoviren-vektor systeme und zelllinien - Google Patents

Adenoviren-vektor systeme und zelllinien

Info

Publication number
ATE336587T1
ATE336587T1 AT95923019T AT95923019T ATE336587T1 AT E336587 T1 ATE336587 T1 AT E336587T1 AT 95923019 T AT95923019 T AT 95923019T AT 95923019 T AT95923019 T AT 95923019T AT E336587 T1 ATE336587 T1 AT E336587T1
Authority
AT
Austria
Prior art keywords
cell lines
adenovirus vector
vector systems
recombinants
adenoviral vectors
Prior art date
Application number
AT95923019T
Other languages
English (en)
Inventor
Imre Kovesdi
Douglas E Brough
Duncan L Mcvey
Joseph T Bruder
Alena Lizonova
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE336587(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genvec Inc filed Critical Genvec Inc
Application granted granted Critical
Publication of ATE336587T1 publication Critical patent/ATE336587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Image Analysis (AREA)
  • Image Processing (AREA)
  • Image Generation (AREA)
AT95923019T 1994-06-10 1995-06-07 Adenoviren-vektor systeme und zelllinien ATE336587T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25841694A 1994-06-10 1994-06-10

Publications (1)

Publication Number Publication Date
ATE336587T1 true ATE336587T1 (de) 2006-09-15

Family

ID=22980456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95923019T ATE336587T1 (de) 1994-06-10 1995-06-07 Adenoviren-vektor systeme und zelllinien

Country Status (7)

Country Link
US (6) US5994106A (de)
EP (2) EP1548118A2 (de)
JP (2) JP3816518B2 (de)
AT (1) ATE336587T1 (de)
CA (1) CA2192442C (de)
DE (1) DE69535178T2 (de)
WO (1) WO1995034671A1 (de)

Families Citing this family (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ES2224113T5 (es) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
CA2192442C (en) * 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
CA2156132A1 (en) * 1994-08-16 1996-02-17 Abraham Bout Recombinant vectors derived from adenovirus for use in gene therapy
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
AU709498B2 (en) * 1994-12-12 1999-09-02 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
EP0760682A4 (de) 1995-02-28 1998-09-09 Univ California Gentransfer-vermittelte therapie zur gefässneubildung
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
EP0821739B1 (de) * 1995-04-17 2003-06-18 The Board Of Regents, The University Of Texas System Adenovirus helfervirus system
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69636120T2 (de) * 1995-11-30 2006-11-30 The Board of Regents, The University of Texas System, Austin Verfahren und zusammensetzungen zur behandlung von krebs
EP0927263A1 (de) * 1996-01-05 1999-07-07 Genetic Therapy, Inc. Rekombinase-vermittelte herstellung adenoviraler vektoren
US6132989A (en) * 1996-06-03 2000-10-17 University Of Washington Methods and compositions for enhanced stability of non-adenoviral DNA
US6730662B1 (en) * 1996-07-05 2004-05-04 Mcgill University Adenovirus E4 proteins for inducing cell death
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
DE69739211D1 (de) * 1996-09-25 2009-02-26 Novartis Ag Verpackungszellinien in der Verwendung zur Erleichterung der Entwicklung hocheffizienter adenoviraler Vektoren
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
JP2000509614A (ja) * 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
PT1944362E (pt) 1997-09-05 2016-01-27 Genzyme Corp Métodos de produção de preparações de alto título de vetores aav recombinantes desprovidos de adjuvantes
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2000012740A2 (en) 1998-08-28 2000-03-09 Duke University ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
EP2942393A1 (de) 1998-09-04 2015-11-11 Genzyme Corporation Verfahren zur erzeugung helferfreier präparate mit hohem titer aus freigesetzten rekombinanten aav-vektoren
US6440944B2 (en) 1998-10-16 2002-08-27 Genvec, Inc. Methods of administering adenoviral vectors
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1198559A1 (de) * 1999-04-23 2002-04-24 Introgene B.V. Mittel und verfahren zum transport von nukleinsäuren
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
US6591543B2 (en) * 2000-04-14 2003-07-15 Kenneth P. Sabine Top water lure with highly active propeller
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US7449562B2 (en) * 2001-06-29 2008-11-11 Novartis Ag PERV screening method and use thereof
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003022311A1 (en) * 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20030087438A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. E1-revertant-free adenoviral composition
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
JP2005532036A (ja) 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
JP4488290B2 (ja) * 2002-01-24 2010-06-23 ザ・スクリップス・リサーチ・インスティテュート 効率的ターゲティングのためのファイバーシャフト変異
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7144870B2 (en) * 2002-02-15 2006-12-05 Research Development Foundation Hyaluronic acid mediated adenoviral transduction
WO2003099859A2 (de) 2002-05-27 2003-12-04 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP1567198A4 (de) * 2002-12-02 2006-05-31 Genvec Inc Materialien und verfahren zur behandlung von augenerkrankungen
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20080124360A1 (en) 2003-01-24 2008-05-29 Seggern Daniel J Von Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4644663B2 (ja) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7026164B2 (en) 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
EP1649028B1 (de) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviralevektoren-basierte impfstoffe
AU2004278517B2 (en) 2003-10-02 2010-04-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
EP1689446B1 (de) 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1687032B1 (de) 2003-11-14 2010-02-24 Genvec, Inc. Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
CA2563313C (en) 2004-04-05 2014-06-03 The Regents Of The University Of California Modulation of nkg2d
CA2563396A1 (en) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
US20060188481A1 (en) * 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20060275812A1 (en) * 2005-06-01 2006-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Assay for agonists and antagonists of ion channels and for regulators of genetic expression
US7825231B2 (en) * 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (de) * 2005-06-13 2009-04-08 Univ Michigan Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
JP2009508470A (ja) 2005-07-21 2009-03-05 アボット・ラボラトリーズ Ｓｏｒｆ構築物並びにポリタンパク質、プロタンパク質及びタンパク質分解による方法を含む複数の遺伝子発現
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
EP1961065A4 (de) 2005-10-31 2009-11-11 Oncomed Pharm Inc Zusammensetzungen und verfahren zur diagnostizierung und behandlung von krebs
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5129149B2 (ja) * 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
BRPI0618441B8 (pt) 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
SI1957528T1 (sl) * 2005-11-30 2013-02-28 University Of Copenhagen Nukleotidno cepivo
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
JP2009543868A (ja) 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド 癌治療に関する方法および組成物
WO2008030605A2 (en) * 2006-09-08 2008-03-13 The Regents Of The University Of Michigan Herv group ii viruses in lymphoma and cancer
EP2101797B1 (de) * 2006-12-01 2015-08-26 HepC Terápia Kereskedelmi és Szolgáltató Zártkörüen Müködö Részvénytársaság Zusammensetzungen und methoden zur behandlung viraler hepatitis
US20080248060A1 (en) * 2007-01-09 2008-10-09 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP2106439B1 (de) * 2007-01-24 2014-11-12 The Regents of the University of Michigan Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
DE602008004476D1 (de) * 2007-03-09 2011-02-24 Vectorlogics Inc Zellen für adenovirusvektor- und proteinherstellung
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
CA2692441C (en) 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
AU2008289172B2 (en) 2007-08-16 2013-01-17 Metabolon, Inc. Metabolomic profiling of prostate cancer
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
US20090202492A1 (en) * 2008-01-25 2009-08-13 University Of South Florida Adenovirus vaccine utilizing ikk as adjuvant
US8193151B2 (en) * 2008-04-25 2012-06-05 Northwestern University Methods for treating atrial or ventricular arrhythmias
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
JP2012504423A (ja) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド 治療用リボヌクレアーゼ
PL2350268T3 (pl) * 2008-11-03 2015-05-29 Crucell Holland Bv Sposób wytwarzania wektorów adenowirusowych
BRPI1004572A2 (pt) 2009-01-09 2016-04-05 Univ Michigan "fusões genéticas recorrentes em câncer
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011045378A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Method for the purification of adenovirus particles
ES2445713T3 (es) 2009-10-15 2014-03-04 Crucell Holland B.V. Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
TW201124535A (en) 2009-10-30 2011-07-16 Abbott Lab SORF constructs and multiple gene expression
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2011057248A2 (en) 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
NZ601424A (en) 2010-02-15 2014-07-25 Crucell Holland Bv Method for the production of ad26 adenoviral vectors
CN102892429B (zh) 2010-03-17 2016-08-31 康奈尔大学 基于被破坏的腺病毒的抗滥用药物疫苗
WO2011116209A2 (en) * 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
TW201823463A (zh) 2010-03-23 2018-07-01 美商英翠克頌公司 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
US8920813B2 (en) * 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
EP3450568A3 (de) 2011-03-04 2019-04-24 Intrexon Corporation Vektoren für bedingte proteinexpression
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
LT2729173T (lt) 2011-07-06 2016-10-10 Sykehuset Sorlandet Hf Egfr taikinių terapija
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
WO2013052832A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vectors and methods of use
IN2014DN03061A (de) 2011-10-05 2015-05-15 Genvec Inc
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
CN107982548A (zh) 2012-02-07 2018-05-04 全球生物疗法有限公司 核酸输送的区室化方法及其组合物和应用
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
EP2827895B1 (de) 2012-03-22 2017-08-09 Janssen Vaccines & Prevention B.V. Impfstoff gegen rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
EP2855511B1 (de) 2012-05-29 2019-07-24 GenVec, Inc. Impfstoff gegen das herpes-simplex virus
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
BR112015013849A2 (pt) 2012-12-21 2017-07-11 Sykehuset Soerlandet Hf terapia direcionada a egfr de distúrbios neurológicos e dor
CA2899353A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
DK2970398T3 (da) 2013-03-13 2024-08-05 Us Health Præfusions-rsv-f-proteiner og anvendelse deraf
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
AP2015008815A0 (en) 2013-04-25 2015-10-31 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
CA2920261C (en) 2013-08-08 2018-04-03 Global Bio Therapeutics, Inc. Clamp device for minimally invasive procedures and uses thereof
ES2711115T3 (es) 2013-09-19 2019-04-30 Janssen Vaccines & Prevention Bv Formulaciones de adenovirus mejoradas
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
MY181175A (en) 2014-11-04 2020-12-21 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
WO2016103238A1 (en) 2014-12-24 2016-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus f proteins and their use
WO2016118642A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
JP6887955B2 (ja) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 組換え体発現系のアッセイ
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
EP3319634B1 (de) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilisierte lösliche präfusionierte rsv-f-polypeptide
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
AU2016328279A1 (en) 2015-09-24 2018-05-10 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
JP6487604B2 (ja) 2015-10-06 2019-03-20 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 生物学的製剤のプラスチック誘起分解を防止する方法
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
WO2017139392A1 (en) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
DK3439672T3 (da) 2016-04-05 2021-02-15 Janssen Vaccines & Prevention Bv Stabiliserede opløselige præfusions-rsv-f-proteiner
CN109922829A (zh) 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合
KR102573534B1 (ko) 2016-05-12 2023-08-31 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US10960070B2 (en) 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
ES2932498T3 (es) 2016-12-05 2023-01-20 Nuritas Ltd Composiciones que comprenden el péptido WKDEAGKPLVK
EP3329930A1 (de) 2016-12-05 2018-06-06 Nuritas Limited Pharmazeutische zusammensetzungen
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
KR20240015743A (ko) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
US11241436B2 (en) 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions
AU2018217935B2 (en) 2017-02-09 2020-04-30 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018176031A1 (en) 2017-03-24 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
AU2018357912B2 (en) 2017-10-31 2023-11-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
JP7438943B2 (ja) 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
MX2020004487A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
WO2019086461A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
EP3714043A4 (de) 2017-11-22 2021-08-11 The Regents of The University of Michigan Zusammensetzungen und verfahren zur behandlung von krebs
JP7317047B2 (ja) 2018-01-23 2023-07-28 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
CN112135622A (zh) 2018-03-06 2020-12-25 普莱西根股份有限公司 乙型肝炎疫苗及其用途
EP3870703A1 (de) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinantes gp120-protein mit v1-schleifendeletion
BR112021013507A2 (pt) 2019-01-10 2021-11-16 Janssen Biotech Inc Neoantígenos da próstata e seus usos
CA3137448A1 (en) 2019-04-25 2020-10-29 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
CN113950333A (zh) 2019-05-15 2022-01-18 扬森疫苗与预防公司 使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
AU2020275455A1 (en) 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
JP2022534741A (ja) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物
US11414785B2 (en) 2019-08-13 2022-08-16 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish IgNAR derived binding domains
KR20220057578A (ko) 2019-09-05 2022-05-09 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
US20220372515A1 (en) 2019-10-03 2022-11-24 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
AU2020361533A1 (en) 2019-10-08 2022-04-28 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
CA3170322A1 (en) 2020-02-11 2021-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 vaccine
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2021222639A2 (en) 2020-04-29 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant human metapneumovirus f proteins and their use
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022035860A2 (en) 2020-08-10 2022-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Replication-competent adenovirus type 4-hiv env vaccines and their use
KR20230051221A (ko) 2020-08-11 2023-04-17 머스큘로스켈레탈 트랜스플랜트 파운데이션 태반-유래 조성물로 심장 병태를 치료하는 방법
US20240228549A1 (en) 2021-04-29 2024-07-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
US20240277829A1 (en) 2021-08-03 2024-08-22 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
CN118139655A (zh) 2021-08-13 2024-06-04 特里奥万斯控股公司 皮肤替代组合物及其产生和使用方法
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
EP4338727A1 (de) 2022-09-14 2024-03-20 Roquette Freres Adenovirus-formulierungen

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
GB2180207A (en) * 1985-03-07 1987-03-25 John Connor Sun visor for a motor vehicle
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5518913A (en) * 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
CA2053187A1 (en) * 1991-10-10 1993-04-11 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
AU692423B2 (en) * 1992-09-25 1998-06-11 Institut National De La Sante Et De La Recherche Medicale Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
ATE307212T1 (de) * 1992-11-18 2005-11-15 Arch Dev Corp Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel
EP0905253A3 (de) * 1992-12-03 2000-11-02 Genzyme Corporation Von allen E4-ORF ausgenommen ORF6 deletierte Adenovirus-Vector
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
WO1994024927A1 (en) 1993-05-04 1994-11-10 Tam, Paul, Y. Method and apparatus for examining tissue by transillumination using near infrared light
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
JP3532566B2 (ja) * 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
JP4190028B2 (ja) 1993-07-13 2008-12-03 アベンテイス・フアルマ・ソシエテ・アノニム 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用
WO1995016772A1 (en) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
CA2117668C (en) * 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
WO1995026411A2 (en) * 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) * 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
CA2156132A1 (en) * 1994-08-16 1996-02-17 Abraham Bout Recombinant vectors derived from adenovirus for use in gene therapy
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
AU709498B2 (en) * 1994-12-12 1999-09-02 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
GB9714303D0 (en) * 1997-07-07 1997-09-10 Pharmacia & Upjohn Spa 5-(3-phenyl-3-oxo-propyl)-1H-tetrazole derivatives

Also Published As

Publication number Publication date
AU2770495A (en) 1996-01-05
EP0784690A1 (de) 1997-07-23
JPH10505484A (ja) 1998-06-02
US20020110545A1 (en) 2002-08-15
US20020031831A1 (en) 2002-03-14
EP1548118A2 (de) 2005-06-29
CA2192442A1 (en) 1995-12-21
JP3816518B2 (ja) 2006-08-30
US20020004040A1 (en) 2002-01-10
DE69535178T2 (de) 2006-12-14
US20010043922A1 (en) 2001-11-22
JP2006136329A (ja) 2006-06-01
DE69535178D1 (de) 2006-09-28
US7195896B2 (en) 2007-03-27
EP0784690B1 (de) 2006-08-16
AU703768B2 (en) 1999-04-01
CA2192442C (en) 2007-09-25
US5994106A (en) 1999-11-30
US6482616B1 (en) 2002-11-19
WO1995034671A1 (en) 1995-12-21

Similar Documents

Publication Publication Date Title
ATE336587T1 (de) Adenoviren-vektor systeme und zelllinien
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
ATE213022T1 (de) Adenovirale vektoren für die gentherapie
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
ATE320503T1 (de) Komplementäre adenovirenvektorsysteme und zellinien
DE69637432D1 (de) Adenovirale vektoren für die gentherapie
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
DE69636055D1 (de) Adenovirale vektoren, die nicht von gruppe c adenovirus typen abgeleitet sind
AU2552795A (en) Safe vectors for gene therapy
NZ323834A (en) Chimeric adenovirus coat protein vectors and methods for gene transfer to cells
EP0866721A4 (de) Adenovirale zielvektoren
EP0688358A4 (de) Verbesserte vektoren für die gentherapy
EP1109896A4 (de) Adenovirale formulierungen zur gentherapie
FI961666A (fi) Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
AU4770297A (en) Receptor-mediated gene transfer system for targeting tumor gene therapy
FI962114A (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
HUP9902150A3 (en) Recombinant adenoviral vectors for human tumour gene therapy
GB2322131B (en) Improved retroviral vectors for gene therapy
AU4096100A (en) Pseudotyped retroviral vector for gene therapy of cancer
AU4839493A (en) Portable intron as an insertion vector for gene insertion
EP1084236A4 (de) Adenovirale vektoren für die gentherapy
AU3036197A (en) Adenovirus vectors for gene therapy
SI0889969T1 (sl) Rekombinantni adenovirusni vektorji za gensko terapijo humanih tumorjev
ZA951451B (en) Host vector system for use in gene therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties